^
Association details:
Biomarker:TMB-H
Cancer:Nasopharyngeal Carcinoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/08/2021
Excerpt:
SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS: Useful in Certain Circumstances...Pembrolizumab (for TMB-H tumors [>/=10 mut/Mb])
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Solid Tumor)
New
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.